Digging into the recent data from the ACCORD Phase 3 Trial of Axsome's AXS-05 in Alzheimer’s Disease AgitationTicker(s): AXSM
Institution: University of Rochester
- Director of the University of Rochester Alzheimer's Disease Care, Research and Education Program.
- Currently manages 150 patients with Alzheimer's Disease Agitation.
- Site PI for studies with solanezumab, gantenerumab, lecanemab, aducanemab, donanemab, semorinemab, pepinemab, AL-002, ATH-1017, and simufilam.
- Internationally recognized in clinical research and considered one of the leading experts in Alzheimer's disease and dementia.
Slingshot Insights Explained
Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.